CAR T Therapy of Solid Cancers: Problems and Progress
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 30 October 2024 | Viewed by 1970
Special Issue Editors
Interests: integrins; cancer microenvironment; tumour invasion; tumour biology; protein structure; biomarker; therapeutic targeting
Special Issue Information
Dear Colleagues,
CAR T cell therapy has revolutionized the treatment of hematological malignancies; however, this clinical success has yet to be seen in the treatment of solid cancers. The major issues presented by solid tumors include trafficking to and penetration into the tumor, and CAR T cell cytotoxic function within the tumor microenvironment.
The reasons for this lack of efficacy appear to be a combination of a powerful immunosuppressive environment driven my multiple elements of the innate and adaptive immune system, in addition to the physical characteristics of the tumor microenvironment, such as desmoplasia and the net positive pressure.
To overcome these challenges, we must investigate the biology of CAR T-cells within immuno-competent models. In this Special Issue of Cancers, entitled “CAR T therapy of solid cancers: Problems and Progress”, we invite experts in the field, many of whom employ syngeneic solid tumor models in mice, to submit articles in the hope that together we can begin to resolve the current lack of clinical success regarding the application of CAR T -cell therapy in solid cancers.
Prof. Dr. John F. Marshall
Dr. Lauren Cutmore
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CAR T therapy
- tumor microenvironment
- solid tumor
- treatment
- immuno-competent models
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
